Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03572530 · ClinicalTrials.gov registry record · Phase 1
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03572530 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 3 participants.
The verdict
NCT03572530, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain. The study's primary objective is to establish the maximum tolerated dose for infusions of 5-Azacytidine into the fourth ventricle in patients with recurrent ependymoma. The study's secondary objective is to assess the antitumor activity of 5-Azacytidine infusions into the fourth ventricle based upon imaging studies and cytology.
Interventions
- DRUG 5-Azacytidine (5-AZA) group 1
- DRUG 5-Azacytidine (5-AZA) group 2
- DRUG 5-Azacytidine (5-AZA) group 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-02-08 |
| Est. Completion | 2020-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03572530
The ClinicalTrials.gov registry entry for NCT03572530 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 5-Azacytidine (5-AZA) group 1 is the first listed.
NCT03572530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03572530 about?
NCT03572530 is a clinical study titled "Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma". This study seeks to determine the optimum dose frequency of 5-Azacytidin (5-AZA) infusions into the fourth ventricle of the brain. The study's primary objective is to establish the maximum tolerated dose for infusions of 5-Azacytidine into the fourth ventricle in patients with recurrent ependymoma. ...
What is the current status of trial NCT03572530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-02-08. Estimated completion is 2020-11-24.
What interventions are being tested in trial NCT03572530?
The interventions under investigation include: 5-Azacytidine (5-AZA) group 1 (DRUG), 5-Azacytidine (5-AZA) group 2 (DRUG), 5-Azacytidine (5-AZA) group 3 (DRUG).
Who is sponsoring clinical trial NCT03572530?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.